Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine after hepatectomy for HBV-related hepatocellular carcinoma
ChiCTR-IPR-15006587Phase 4Completed
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telbivudine in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Rate of HBV reactivation, Rate of tumor recurrence and 1 more. Started Nov 2008; status: completed.
02
Drugs
telbivudine
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-IPR-15006587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006587.